Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap-Core Interface of HIV-1 Protease

about

Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap-Core Interface of HIV-1 Protease

Item

http://www.wikidata.org/entity/Q57063482

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Drug Resistance Mutation L76V ...... re Interface of HIV-1 Protease

@en

Drug Resistance Mutation L76V ...... re Interface of HIV-1 Protease

@nl

type

Item

label

Drug Resistance Mutation L76V ...... re Interface of HIV-1 Protease

@en

Drug Resistance Mutation L76V ...... re Interface of HIV-1 Protease

@nl

prefLabel

Drug Resistance Mutation L76V ...... re Interface of HIV-1 Protease

@en

Drug Resistance Mutation L76V ...... re Interface of HIV-1 Protease

@nl

P1476

Drug Resistance Mutation L76V ...... re Interface of HIV-1 Protease

@en

P2093

Arun K Ghosh

http://www.w3.org/2001/XMLSchema#string

Irene T Weber

http://www.w3.org/2001/XMLSchema#string

Robert W Harrison

http://www.w3.org/2001/XMLSchema#string

Ying Zhang

http://www.w3.org/2001/XMLSchema#string

Yuan-Fang Wang

http://www.w3.org/2001/XMLSchema#string

P2860

A short history of SHELX

Processing of X-ray diffraction data collected in oscillation mode

X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease

Unique Thermodynamic Response of Tipranavir to Human Immunodeficiency Virus Type 1 Protease Drug Resistance Mutations

Conformational flexibility in the flap domains of ligand-free HIV protease

Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV-1 protease: Relevance to drug resistance

Probing Multidrug-Resistance and Protein-Ligand Interactions with Oxatricyclic Designed Ligands in HIV-1 Protease Inhibitors

The L76V Drug Resistance Mutation Decreases the Dimer Stability and Rate of Autoprocessing of HIV-1 Protease by Reducing Internal Hydrophobic Contacts

TMC310911, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, Shows In Vitro an Improved Resistance Profile and Higher Genetic Barrier to Resistance Compared with Current Protease Inhibitors

Novel P2 Tris-tetrahydrofuran Group in Antiviral Compound 1 (GRL-0519) Fills the S2 Binding Pocket of Selected Mutants of HIV-1 Protease

P304

12132-12140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACSOMEGA.8B01683

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andres Wong-Sam

P577

2018-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30288468

http://www.w3.org/2001/XMLSchema#string

P932

6167001

http://www.w3.org/2001/XMLSchema#string